Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification
- 1 August 2003
- journal article
- research article
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 5 (3) , 155-159
- https://doi.org/10.1016/s1525-1578(10)60467-9
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- HER2/neuAmplification in Breast CancerAmerican Journal of Clinical Pathology, 2002
- Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu StatusLaboratory Investigation, 2002
- The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapySeminars in Cancer Biology, 1999
- c-erbB2 expression predicts tamoxifen efficacy in breast cancer patientsBreast Cancer Research and Treatment, 1998
- Her-2/neu as a Predictive Marker of Response to Breast Cancer TherapyBreast Cancer Research and Treatment, 1998
- The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A reviewGene, 1995
- ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancerCancer Letters, 1994
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987